PainReform completed its acquisition of DeepSolar, enhancing its portfolio in the clean energy sector with AI-driven solar analytics.
Quiver AI Summary
PainReform Ltd. has successfully completed its acquisition of DeepSolar, an AI-driven solar analytics platform, from BladeRanger Ltd. This strategic move marks PainReform's entry into the clean energy sector, utilizing DeepSolar’s technology to enhance solar asset management efficiency and profitability. The acquisition is expected to generate recurring revenue through DeepSolar's Software-as-a-Service model, reduce operational costs for customers, and open up multiple revenue growth avenues targeting various solar market segments. PainReform anticipates that DeepSolar's AI capabilities will differentiate it in the competitive renewable energy landscape and provide long-term value. The integration of DeepSolar's team and technology aligns with PainReform’s broader strategy to invest in high-margin, technology-oriented sectors while still focusing on its pharmaceutical innovations.
Potential Positives
- The acquisition of DeepSolar expands PainReform's portfolio into the high-growth clean energy sector, leveraging technology with significant revenue potential.
- DeepSolar’s AI-driven platform optimizes solar farm efficiency, reducing operational costs for customers by up to 30%, which can enhance customer profitability.
- The Software-as-a-Service (SaaS) model of DeepSolar is expected to generate recurring high-margin revenue streams, boosting PainReform’s financial stability and growth prospects.
- The integration of DeepSolar's technology positions PainReform as a potential technology leader in solar asset optimization, differentiating it within the competitive renewable energy market.
Potential Negatives
- The acquisition of DeepSolar may distract management from PainReform's core competencies in pharmaceutical development, especially if integration proves challenging.
- Forward-looking statements indicate uncertainties surrounding the expected benefits and successful integration of the acquired business, which could impact investor confidence.
- The reliance on the performance of DeepSolar poses a significant risk, as any failure to meet expectations could adversely affect PainReform's financial stability and stock value.
FAQ
What is the recent acquisition by PainReform?
PainReform acquired 100% of DeepSolar, an AI-driven solar analytics platform, from BladeRanger Ltd., marking its entry into the clean energy sector.
How will DeepSolar benefit PainReform?
DeepSolar is expected to generate recurring revenue, reduce operational costs for customers, and enhance PainReform's technological differentiation in the solar market.
What is DeepSolar's business model?
DeepSolar operates on a Software-as-a-Service (SaaS) model, providing high-margin revenue streams from commercial solar operators and residential users.
What market opportunities does DeepSolar address?
DeepSolar targets major solar producers and residential users, aiming to optimize solar farm efficiency and profitability in a rapidly growing market.
Who will manage DeepSolar after the acquisition?
The core team from DeepSolar at BladeRanger will join PainReform to ensure a seamless transition and continued operational success.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PRFX Hedge Fund Activity
We have seen 0 institutional investors add shares of $PRFX stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 276,000 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $170,678
- VIRTU FINANCIAL LLC removed 20,055 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $12,402
- OSAIC HOLDINGS, INC. removed 4,600 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $2,844
- UBS GROUP AG removed 4,549 shares (-70.0%) from their portfolio in Q4 2024, for an estimated $15,261
- TWO SIGMA SECURITIES, LLC removed 4,308 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $14,453
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
TEL AVIV, Israel, March 05, 2025 (GLOBE NEWSWIRE) --
PainReform Ltd.
(Nasdaq: PRFX) ("
PainReform
" or the "
Company
"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the successful closing of its
previously announced
acquisition of 100% of the business activity of DeepSolar, an AI-driven solar analytics platform, from BladeRanger Ltd, a public company registered under the laws of the State of Israel, whose shares are listed for trading on Tel Aviv Stock Exchange under the ticker “BLRN”. This acquisition marks an important milestone for PainReform as it expands into a high-growth sector with significant revenue potential, leveraging DeepSolar’s proprietary AI-driven solutions to optimize solar energy asset management.
The acquisition solidifies PainReform’s entry into the rapidly expanding clean energy sector, where DeepSolar’s software optimizes solar farm efficiency and profitability. With the transaction now complete, PainReform aims to broaden DeepSolar’s customer base, as well as increase penetration within existing customers, targeting major utility-scale solar operators, independent power producers, and residential solar users.
DeepSolar provides a cutting-edge AI analytics platform that enhances energy production while reducing operational inefficiencies. The platform seamlessly integrates with SCADA systems to provide monitoring, predictive maintenance, and actionable insights, reducing costs and boosting profitability for solar asset owners.
PainReform expects DeepSolar to contribute long-term value by:
Generating Recurring Revenue Streams
: DeepSolar’s Software-as-a-Service (SaaS) model is designed to provide a steady, high-margin revenue from commercial solar operators, asset owners and residential users.
Reducing Operational Costs for Customers
: AI-driven automation and analytics are expected to cut maintenance expenses by up to 30%, directly improving customer profitability.
Achieving Broad Market Penetration
: DeepSolar’s target customers span major energy producers, residential solar users, and grid operators, creating multiple avenues for revenue growth.
Enhancing Technological Differentiation
: DeepSolar’s AI capabilities offer a distinct advantage in the competitive renewable energy market, setting PainReform apart as a potential future technology leader in solar asset optimization.
According to the
SolarPower Europe
report on the solar market from 2021–2026, the solar energy market is expanding rapidly, generating over 1 terawatt (TW) of energy and growing at an annual rate of 25.32%. In 2024 alone, the residential solar market reached a valuation of $94.2 billion according to the
Solar Industry Research Data
report, and is expected to grow at 8% annually through 2034. DeepSolar’s solutions directly address the inefficiencies in solar asset management, presenting a massive market opportunity for PainReform to capture value in both the B2B and B2C segments.
“With DeepSolar officially part of our portfolio, we believe PainReform is positioned to capitalize on the accelerating global transition to clean energy,” said Ehud Geller, Chairman and interim CEO of PainReform. “This acquisition aligns with our broader strategy to invest in high-margin, technology-driven sectors while continuing to advance our pharmaceutical innovations. The integration of AI-powered analytics into solar energy management potentially opens a vast new revenue channel and enhances our ability to create shareholder value.”
The Company expects DeepSolar’s scalable SaaS platform to drive revenue growth and plans to explore strategic partnerships with utility companies, solar technology providers, and smart grid operators.
While PainReform remains committed to advancing its core drug delivery technologies, including its proprietary PRF-110 for post-surgical pain relief, it believes that the addition of DeepSolar represents a forward-thinking investment in a high-growth sector that is designed to enhance long-term shareholder value.
In connection with the acquisition, PainReform received all rights, title and interest in certain (i) the agreements, (ii) intellectual property, (iii) accounts receivable, (iv) equipment, (v) Deep Solar’s reputation and customer relations associated with their business, (vi) the “My DeepSolar” application and platform, and (vi) all rights, title and interest in, to or arising from any of the foregoing assets, properties and rights (whether real, personal or mixed, tangible or intangible, wherever located), each as set forth or defined in the Agreement (collectively, the “Acquired Assets”). In consideration for the sale of the Acquired Assets, BLRN received upon closing (1) 178,769 ordinary shares of the Company, representing 9.9% of the issued and outstanding share capital of PainReform (after such issuance), and (2) 223,792 pre-funded warrants to purchase 223,792 ordinary shares. After the increase of the PainReform share capital at its shareholders meeting convened for April 3, 2025, PainReform will issue the remaining securities which include (1) 685,004 pre-funded milestone warrants to purchase 685,004 ordinary shares, (2) 1,087,565 warrants-A to purchase 1,087,565 ordinary shares, and (3) 1,087,565 warrants-B to purchase 1,087,565 ordinary shares. In addition, the core team managing DeepSolar at BLRN are joining PainReform.
Pursuant to the Agreement, BLRN may not exercise any of the pre-funded warrants, pre-funded milestone warrants, warrants-A or warrants-B held by it (or any assignee or transferee of BLRN), if, following such exercise, BLRN (including any assignee or transferee) holds shares of the Company which exceed 9.99% of the issued and outstanding share capital of PainReform.
About PainReform
PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. The Company's proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. For more information, please visit
www.painreform.com
.
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements about PainReform’s expectations, beliefs and intentions including with respect to the anticipated benefits to PainReform of the acquisition of DeepSolar, the anticipated market opportunity and potential for revenue growth.. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward- looking statements, including, but not limited to, the following: our ability to realize the anticipated benefits of the proposed transaction, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; our ability to continue as a going concern, our history of significant losses, our need to raise additional capital and our ability to obtain additional capital on acceptable terms, or at all; our dependence on the success of our initial product candidate, PRF-110; the outcomes of preclinical studies, clinical trials and other research regarding PRF-110 and future product candidates; our limited experience managing clinical trials; our ability to retain key personnel and recruit additional employees; our reliance on third parties for the conduct of clinical trials, product manufacturing and development; the impact of competition and new technologies; our ability to comply with regulatory requirements relating to the development and marketing of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights and our ability to operate our business without infringing the intellectual property rights of others; the overall global economic environment; our ability to develop an active trading market for our ordinary shares and whether the market price of our ordinary shares is volatile; our ability to maintain our listing on the Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business, including due to the current war in Israel. More detailed information about the risks and uncertainties affecting us is contained under the heading "Risk Factors" included in the Company's most recent Annual Report on Form 20-F and in other filings that we have made and may make with the Securities and Exchange Commission in the future.
Contact:
Crescendo Communications, LLC
Tel: 212-671-1021
Email:
prfx@crescendo-ir.com
Dr. Ehud Geller
Chairman and interim Chief Executive Officer PainReform Ltd.
Tel: +972-54-4236711
Email:
egeller@medicavp.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
